Back to Search
Start Over
The effectiveness of ziprasidone in treating impaired quality of life in schizophrenia: A 12-month, open-label, flexible-dose, naturalistic observational study of patients undergoing usual care
- Source :
- Progress in Neuro-Psychopharmacology and Biological Psychiatry. 31:1470-1477
- Publication Year :
- 2007
- Publisher :
- Elsevier BV, 2007.
-
Abstract
- Objective Health related quality of life (HRQL) has become an important outcome measure in the treatment of psychiatric disorders. This long-term observational study examined ziprasidone-induced improvement in satisfaction with HRQL in schizophrenia patients treated under real-world conditions. Method Seventy schizophrenia patients with persistent symptoms or troublesome side effects were assigned to a 12-month, open-label, flexible-dose (40–160 mg/d), large-scale, naturalistic trial. Outcome measures were taken at baseline, 6, and 12 months, and included the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), severity of symptoms, distress, and side effects. Results Thirty-two patients fully completed the study protocol. Patients reported poorer general HRQL compared with healthy subjects. At the end of the study, significant improvement in general activity, and satisfaction with life was observed. The effect sizes for these changes were moderate (0.55, and 0.72, respectively). After Bonferroni correction for multiple comparisons improvement in satisfaction with general activity remained significant. No significant changes were noted in other Q-LES-Q dimensions. Improvement in general activity was associated with a reduction in the severity of symptoms and emotional distress, but was unrelated to the ziprasidone daily dose, side effect scores, and concomitantly prescribed antidepressants, anxiolytics, mood stabilizers, or antiparkinson drugs. Conclusion This study indicates that ziprasidone treatment resulted in the improvement of the satisfaction with general activity that tended to increase over time, from month 6 onwards. This effect was associated with reduction in the severity of clinical symptoms, and emotional distress.
- Subjects :
- Adult
Male
medicine.medical_specialty
Side effect
Piperazines
Quality of life
Surveys and Questionnaires
medicine
Humans
Ziprasidone
Psychiatry
Biological Psychiatry
Psychiatric Status Rating Scales
Pharmacology
Analysis of Variance
Middle Aged
medicine.disease
Antiparkinson drug
Thiazoles
Distress
Mood
Schizophrenia
Chronic Disease
Quality of Life
Physical therapy
Female
Schizophrenic Psychology
Observational study
Psychology
Antipsychotic Agents
medicine.drug
Subjects
Details
- ISSN :
- 02785846
- Volume :
- 31
- Database :
- OpenAIRE
- Journal :
- Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Accession number :
- edsair.doi.dedup.....58325cc9057c462dbf4945f5b78f9905